Key result
CYP2C9*2 was most abundant in Europe and the Middle East, whereas CYP2C9*3 was highly prevalent in South Asia and the UAE, indicating up to 40% of patients in some regions may need dose reductions for drugs like warfarin and phenytoin.
Why the study?
Genetic variability in CYP2C9 affects drug efficacy and safety, but a global map of this variability and its functional consequences was lacking.
Systematic Review (n=81,662)
A comprehensive global map of CYP2C9 genetic variability reveals significant ethnogeographic differences, indicating that up to 40% of patients in Southern Europe and the Middle East might require warfarin dose reductions.
No takes yet. Share an insight, caveat, or question.
May guide ancestry-informed dosing of CYP2C9 substrates; extends global pharmacogenomic maps but leaves outcome validation open.
Zhou et al. (2023) conducted a systematic review in CYP2C9 genetic variability (n=81,662). CYP2C9 variant alleles (*2, *3, *5, *6, *8, *11, *13, *14) vs. CYP2C9 wild-type / reference allele was evaluated on Global allele frequencies of CYP2C9 variants and inferred metabolizer phenotypes. CYP2C9*2 was most abundant in Europe and the Middle East, whereas CYP2C9*3 was highly prevalent in South Asia and the UAE, indicating up to 40% of patients in some regions may need dose reductions for drugs like warfarin and phenytoin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: